Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Stroke prevention in the young child with sickle cell anaemia
Annals of Hematology, 05/28/09
Roberts L et al. - The authors report five episodes of stroke in under 3s and outcome of TCD screening in children under 3, compared to over 3. TCD analysis was as successful in the 2–3-year age group as in the 3–4-year group. The authors therefore propose that all children with SCA should be offered TCD screening from the age of 2 years. Furthermore, infants with high risk features of SCA should undergo a first attempt at TCD screening even earlier.
Today in Anemia/Polycythemia...keeping you current
Receive free subspecialty "5-minute updates" via email
A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases
World Journal of Gastroenterology, 10/12/09
Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 11/05/09
Sickle cell disease and stroke
Blood, 10/13/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the childrens oncology group
Journal of Clinical Oncology, 10/12/09
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


